A Clinical Study on the Safety, Tolerability and Efficacy of Neoantigen-based Personalized mRNA Therapy iNeo-Vac-R01 Plus PD-1 Inhibitor in Adjuvant Treatment of Liver Cancer Post Radical Resection

NCT07495215 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Yinghua Xu